Phase II
The primary endpoint was change from baseline to 76 weeks in the Integrated Alzheimer’s Disease Rating Scale (iADRS).
When Chinook Therapeutics looks at 2021, it foresees a host of clinical trials that will bring precision medicine to the kidney disease space.
The new year began with a fairly low level of clinical trial news. Here’s a look.
This morning, Alnylam announced vutrisiran met primary and all secondary endpoints. Here’s everything you need to know about the drug and its purpose.
2021 is off to a hopeful start for some companies, executives and scientists, while others are forced to fold programs and recalibrate.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for January 5, 2021.
Calithera Biosciences reported that its CANTATA clinical trial of telaglenastat in patients with advanced or metastatic renal cell carcinoma (RCC) failed to hit the primary endpoint.
Even with the holidays among us, there were a number of clinical trial announcements. Here’s a look.
In October, the FDA placed a clinical hold on the company’s Huntington’s disease gene therapy before that asset could make its way into the clinic.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for December 29, 2020.
PRESS RELEASES